HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Heather Eng Selected Research

Cytochrome P-450 CYP3A

5/2016The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Heather Eng Research Topics

Disease

6COVID-19
04/2024 - 02/2021
6Human Influenza (Influenza)
01/2021 - 11/2011
3Cough
01/2020 - 11/2011
2Infections
01/2019 - 11/2011
1Thrombosis (Thrombus)
11/2021
1Hemorrhage
11/2021
1Respiratory Sounds (Crackle)
01/2019
1Rheumatoid Arthritis
01/2018
1Hyperbilirubinemia
10/2016
1Cholestasis
10/2016
1Muscular Diseases (Myopathy)
05/2016
1Rhabdomyolysis
05/2016
1Breast Neoplasms (Breast Cancer)
05/2016
1Diabetic Nephropathies (Diabetic Nephropathy)
01/2016
1Cardiovascular Diseases (Cardiovascular Disease)
11/2015
1Heart Failure
09/2014
1Major Depressive Disorder (Major Depressive Disorders)
05/2013
1Agranulocytosis (Granulocytopenia)
06/2012
1Colonic Neoplasms (Colon Cancer)
06/2012
1Neutropenia
06/2012
1Type 2 Diabetes Mellitus (MODY)
12/2011
1Ovarian Neoplasms (Ovarian Cancer)
03/2002

Drug/Important Bio-Agent (IBA)

6Antiviral Agents (Antivirals)IBA
04/2024 - 09/2016
4VaccinesIBA
04/2024 - 01/2019
3Influenza Vaccines (Influenza Vaccine)FDA Link
01/2020 - 07/2015
2nirmatrelvir and ritonavir drug combinationIBA
04/2024 - 01/2022
2Protease Inhibitors (Protease Inhibitor)IBA
01/2022 - 10/2021
2Peptide Hydrolases (Proteases)FDA Link
01/2022 - 02/2021
2Fusidic Acid (Fucithalmic)IBA
10/2016 - 05/2016
2Anti-Infective Agents (Microbicides)IBA
10/2016 - 05/2016
2Peptides (Polypeptides)IBA
05/2016 - 09/2014
1SARS-CoV-2 3C-like proteinaseIBA
04/2024
1Ritonavir (Norvir)FDA Link
01/2022
1PeptidomimeticsIBA
01/2022
1nirmatrelvirIBA
01/2022
1apixabanIBA
11/2021
1AnticoagulantsIBA
11/2021
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2021
1Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
01/2018
1dagrocoratIBA
01/2018
1fosdagrocoratIBA
01/2018
1Anti-Bacterial Agents (Antibiotics)IBA
10/2016
1GlucuronidesIBA
10/2016
1BilirubinIBA
10/2016
1Neuraminidase (Sialidase)IBA
09/2016
1Proteins (Proteins, Gene)FDA Link
05/2016
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
05/2016
1AnionsIBA
05/2016
1Cytochrome P-450 CYP3AIBA
05/2016
1Digoxin (Digitek)FDA LinkGeneric
05/2016
1Rosuvastatin Calcium (Crestor)FDA Link
05/2016
1Atorvastatin (Lipitor)FDA Link
05/2016
1Simvastatin (Zocor)FDA LinkGeneric
05/2016
1indoleIBA
01/2016
1Adenosine Monophosphate (AMP)IBA
01/2016
1Carboxylic AcidsIBA
01/2016
1Protein Kinases (Protein Kinase)IBA
01/2016
1Peroxidase (Myeloperoxidase)IBA
11/2015
12- (6- (5- chloro- 2- methoxyphenyl)- 4- oxo- 2- thioxo- 3,4- dihydropyrimidin- 1(2H)- yl)acetamideIBA
11/2015
1Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
05/2013
1Antidepressive Agents (Antidepressants)IBA
05/2013
1Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA
06/2012
1AntithrombinsIBA
06/2012
1AutoantibodiesIBA
06/2012
1Captopril (Capoten)FDA LinkGeneric
06/2012
1Cocaine (Cocaine HCl)IBA
06/2012
1Fluorouracil (Carac)FDA LinkGeneric
06/2012
1HLA Antigens (Human Leukocyte Antigens)IBA
06/2012
1Levamisole (Decaris)FDA Link
06/2012
1Methimazole (Thiamazole)FDA LinkGeneric
06/2012
1PropylthiouracilFDA Link
06/2012
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
12/2011
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
11/2011
1Hand SanitizersIBA
11/2011
1insulin receptor-related receptor (IRR)IBA
11/2011

Therapy/Procedure

3Therapeutics
04/2024 - 11/2021
1Ambulatory Care (Outpatient Care)
07/2015
1Drug Therapy (Chemotherapy)
03/2002